JNJ Stock Chart & Fundamental Analysis

Interactive Chart

About Johnson & Johnson

Name

Johnson & Johnson

CEO

Joaquin Duato

Website

www.jnj.com

Industry

Healthcare

Year Founded

1886

Employees

141,700

Johnson & Johnson develops and sells healthcare products across pharmaceuticals and medical technology, with shares listed on the NYSE under JNJ. In FY2025 it generated $94.2 billion in revenue. The company operates in healthcare as a maker of medicines and care-delivery products for hospitals, medical professionals, and retail channels.

Analyst Ratings

Consensus Recommendation

Buy5

Hold0

Sell2

Fundamentals & Financials

Revenue (TTM)

$96.3B

Net Income (TTM)

$21B

EPS (TTM)

$8.67

ROA (TTM)

10.47%

Current Ratio

1.03

Dividend Yield

0.53%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q1 FY2026	Q4 FY2025	Q3 FY2025
Revenue	$24,062M	$24,564M	$23,993M
Cost of Sales	$6,859M	$7,968M	$7,303M
Gross Profit	$17,203M	$16,596M	$16,690M
Operating Income	$6,395M	$5,591M	$7,096M
Net Income	$5,235M	$5,116M	$5,152M
EPS	$2.14	$2.1	$2.14

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

Johnson & Johnson's Technical Indicators Summary

JNJ shows strong technical alignment with price well above short-, medium- and long-term moving averages and a bullish MACD, supported by positive ADX that signals a meaningful trend. Momentum measures are robust though RSI is elevated, indicating overbought readings; volatility is contained with a moderate ATR and OBV confirms buying participation. The pivot lies well below the current level, reinforcing the strength of the advance. Technical takeaway: Strong Buy.

Buy

5 signals

Neutral

0 signals

Sell

2 signals

Overall: Bullish71% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	73.12	Sell	RSI (73.12) > 70, indicating overbought conditions.
Stochastic %K (14, 3, 3)	87.75	Sell	Stochastic (87.75) > 80, indicating overbought.
CCI (20)	163.28	Buy	CCI (163.28) > 100, indicating strong upward momentum.
WPR (14)	-0.17	Sell	Williams %R (-0.17) > -20, indicating overbought.
Momentum (10)	28.84	Buy	Momentum (28.84) is positive.
MFI	58.08	Neutral	MFI (58.08) is neutral.
MACD Level (12, 26)	6.97	Buy	Confirmed uptrend: MACD (6.97) is positive and above its signal line (4.46).
Bollinger Bands	$220.38 - $261.79	Sell	Price ($263.04) is above the upper band ($261.79).
ATR (14)	$5.74 (2.18%)	Neutral	Moderate Volatility (2.18%).
ADX (14)	26.51	Buy	Strong uptrend (ADX > 25) with bullish directional movement. ADX(26.51), +DI(44.25), -DI(13.31)
OBV	233,086,422	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(233,086,422), 20D-SMA-OBV(200,168,840)
Classic Pivot Point	$253.09	Buy	Price ($263.04) has broken above resistance R1 ($255.09) — bullish breakout potential.
Fibonacci Pivot Point	$253.09	Buy	Price ($263.04) has broken above resistance R1 ($254.28) — bullish breakout potential.
Simple Moving Averages	$218.94 - $246.88(5 indicators)	Buy	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.
Exponential Moving Averages	$215.22 - $249.96(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

JNJ closed 3.57% above yesterday’s level of 253.98. By the close, sector strength was clear, with a 2.65% gain underpinning risk appetite. JNJ rose as sector strength lifted risk appetite, with news that JNJ won naming rights for a New Brunswick life-science hub.

Trading Volume

vs S&P 500 Today

Strong Outperformance

+9.39%

52-Week Position

Near highs

100%

Updated: July 2, 2026 at 20:09 UTC